三爱健康集团二零二三年年报

CONTENTS 目录 CorporateInformation 公司资料 2 ManagementDiscussionandAnalysis 管理层讨论及分析 4 CorporateGovernanceReport 企业管治报告 14 Directors’Biographies 董事履历 28 Directors’Report 董事会报告 32 IndependentAuditor’sReport 独立核数师报告 50 ConsolidatedStatementofProfitorLoss 综合损益表 57 ConsolidatedStatementofProfitorLossandOtherComprehensiveIncome 综合损益及其他全面收益表 58 ConsolidatedStatementofFinancialPosition 综合财务状况表 59 ConsolidatedStatementofChangesinEquity 综合权益变动表 60 ConsolidatedStatementofCashFlows 综合现金流量表 62 NotestotheConsolidatedFinancialStatements 综合财务报表附注 64 Five-YearFinancialSummary 五年财务概要 159 CorporateInformation 公司资料 BOARDOFDIRECTORS ExecutiveDirectors Mr.ChenChengqingProfessorZhangRongqingMr.GaoBorui Mr.YuanChaoyangMr.SheHao Non-executiveDirector Mr.XiuYuan IndependentNon-executiveDirectors ProfessorZhuYiZhunMr.KhorKhieLiemAlexMr.ZhangRuigen COMPANYSECRETARY Ms.LiYuenShan AUTHORIZEDREPRESENTATIVES Mr.SheHao Ms.LiYuenShan AUDITCOMMITTEE Mr.KhorKhieLiemAlex(Chairman) ProfessorZhuYiZhunMr.ZhangRuigen REMUNERATIONCOMMITTEE Mr.KhorKhieLiemAlex(Chairman) ProfessorZhuYiZhunMr.ZhangRuigen ProfessorZhangRongqing NOMINATIONCOMMITTEE Mr.ZhangRuigen(Chairman) ProfessorZhuYiZhunMr.KhorKhieLiemAlex ProfessorZhangRongqing AUDITOR MazarsCPALimited HONGKONGLEGALADVISOR RaymondSiu&LawyersUnits1302–1303&1802 RuttonjeeHouseRuttonjeeCentre11DuddellStreetCentral,HongKong 董事会执行董事陈成庆先生张荣庆教授高伯瑞先生袁朝阳先生畲昊先生 非执行董事 修远先生 独立非执行董事朱依谆教授许麒麟先生张瑞根先生 公司秘书 李婉珊女士 法定代表畲昊先生李婉珊女士 审核委员会 许麒麟先生（主席）朱依谆教授 张瑞根先生 薪酬委员会 许麒麟先生（主席）朱依谆教授 张瑞根先生张荣庆教授 提名委员会 张瑞根先生（主席）朱依谆教授 许麒麟先生张荣庆教授 核数师 中审众环（香港）会计师事务所有限公司 香港法律顾问萧镇邦律师行香港中环 都爹利街11号律敦治中心律敦治大厦 1302–1303及1802室 2SanaiHealthIndustryGroupCompanyLimited•AnnualReport2023 CorporateInformation 公司资料 PRINCIPALBANKERS NanyangCommercialBankLimitedHangSengBankLimited ChinaConstructionBank IndustrialandCommercialBankofChinaLimitedChinaCiticBankCorporationLimited REGISTEREDOFFICE GrandPavilionHibiscusWay 802WestBayRoad P.O.Box31119KY1-1205CaymanIslands PRINCIPALPLACEOFBUSINESSINHONGKONG Unit5,7/F.NanyangPlaza57HungToRoadKwunTong Kowloon,HongKong SHAREREGISTRARSANDTRANSFEROFFICES Principalshareregistrarandtransferoffice RoyalBankofCanadaTrustCompany(Cayman)Limited 4thFloor,RoyalBankHouse 24SheddenRoad,GeorgeTownGrandCaymanKY1-1110CaymanIslands HongKongbranchshareregistrarandtransferofficeComputershareHongKongInvestorServicesLimited17MFloor HopewellCentre 183Queen’sRoadEastWanchai,HongKong STOCKCODE 1889 WEBSITE www.1889hk.com 主要往来银行 南洋商业银行有限公司恒生银行有限公司 中国建设银行 中国工商银行股份有限公司中信银行股份有限公司 注册办事处GrandPavilionHibiscusWay 802WestBayRoad P.O.Box31119KY1-1205CaymanIslands 香港主要营业地点 香港九龙观塘 鸿图道57号南洋广场7楼5室 股份过户登记处 股份过户登记总处 RoyalBankofCanadaTrustCompany (Cayman)Limited 4thFloor,RoyalBankHouse 24SheddenRoad,GeorgeTownGrandCaymanKY1-1110CaymanIslands 股份过户登记处香港分处 香港中央证券登记有限公司 香港湾仔 皇后大道东183号合和中心 17M楼 股份代号 1889 网址 www.1889hk.com 三爱健康产业集团有限公司‧二零二三年年度报告3 4SanaiHealthIndustryGroupCompanyLimited•AnnualReport2023 BUSINESSREVIEW Duringtheyearended31December2023(the“ReportingPeriod”),theGroupwasprincipallyengagedinthreebusinesses:(i)pharmaceuticalproductsbusiness;(ii)financeleasingbusiness;(iii)genetictestingandmoleculardiagnosticservices.Thethreebusinessesarestatedasbelow: PharmaceuticalProductsBusiness SincethesuccessfultransferoftheproductionlineoftheGroupfromour51%-ownedsubsidiarytoourwholly-ownedsubsidiaryinAugust2022,thecoreproductioncentreaswellastheexclusivesaleschanneloftheGroup’sowndevelopedpharmaceuticalproductshasbeenundercontrolofourwholly-ownedsubsidiaryduringtheReportingPeriod.Assuch,theGrouphasbeenabletoincreaseitsshareofprofitgeneratedfromthesalesofthissegmentasasignificantportionofsuchprofitisnolongerrequiredtobesharedbythenon-controllinginterestsofour51%-ownedsubsidiaryasinthepastyears.However,thereisaverysubstantialincreaseinthegeneralcostaswellasashortageinthevolumeofsupplyoftraditionalChineseherbalmaterialsinthePRCsincethestartoftheyearof2023whichhasadverselyaffectedthegrossprofitmarginaswellasthevolumeofthesalesofourowndevelopedpharmaceuticalproductsintheReportingPeriod. TheGroupwilltakeamorecautiousapproachtoincreaseitsmarketsharebyexpandingitsproductioncapacityandpromotingitsowndevelopedpharmaceuticalproductsastheactualpaceandprogressofeconomicrecoveryinChinahasnotbeenaspromisingandencouragingasoriginallyexpectedduringtheReportingPeriod. FujianZhixin,anindirectwholly-ownedsubsidiaryoftheCompany,actsasasalesagentnationwideforherbalmedicalmaterials,Chineseherbalmedicine,Chinesepatentmedicine,chemicaldrugpreparations,antibioticpreparations,biochemicalpharmaceuticals,biologicalproducts,healthcareproductsandfoodproducts. DuringtheReportingPeriod,therevenuederivedfromthepharmaceuticalproductsbusinessdecreasedby34.15%toapproximatelyRMB100.52million(2022:approximatelyRMB152.65million).TheprofitderivedfromthepharmaceuticalproductsbusinessdecreasedtoRMB19.82millionfortheReportingPeriod,representingadecreaseofapproximately72.05%ascomparedtoRMB70.90millionforthecorrespondingperiodin2022. 业务回顾 截至二零二三年十二月三十一日止年度 （“报告期”），本集团主要从事三项业务： (i)医药产品业务；(ii)融资租赁业务；(iii) 基因检测及分